Related Experiment Video
Updated: May 28, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
GUCY2C-targeted cancer immunotherapy: past, present and future
Adam E Snook1, Michael S Magee, Scott A Waldman
1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1020 Locust Street, JAH 348A, Philadelphia, PA 19107, USA. Adam.Snook@jefferson.edu
Immunologic Research
|November 1, 2011
Summary
Guanylyl cyclase C (GUCY2C) is a promising target for colorectal cancer immunotherapy. Researchers developed a GUCY2C vaccine (Ad5-GUCY2C) showing safety and efficacy in mice, now advancing to clinical trials.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Guanylyl cyclase C (GUCY2C) is highly expressed in colorectal cancers and intestinal cells, making it an ideal immunotherapy target.
- Colorectal cancer remains a significant global health challenge with limited effective treatment options for many patients.
Purpose of the Study:
- To evaluate the potential of GUCY2C as a target antigen for colorectal cancer immunotherapy.
- To develop and test a recombinant adenoviral vector vaccine (Ad5-GUCY2C) for colorectal cancer.
- To explore next-generation GUCY2C-targeted therapies for advanced colorectal cancer.
Main Methods:
- Development and testing of a recombinant adenoviral vector expressing GUCY2C (Ad5-GUCY2C).
- Preclinical evaluation in murine models to assess safety and efficacy.
- Planning for Phase I clinical trials in colorectal cancer patients with minimal residual disease.
- Development of chimeric antigen receptor (CAR)-T cell therapies targeting GUCY2C.
Main Results:
- Ad5-GUCY2C demonstrated safety and effectiveness against GUCY2C-expressing tumors in preclinical studies.
- The Ad5-GUCY2C vaccine is ready for Phase I clinical testing in specific patient populations.
- Second-generation therapies, including CAR-T cells, are under development for advanced disease.
Conclusions:
- GUCY2C-targeted immunotherapies represent a promising strategy to address unmet needs in colorectal cancer treatment.
- A family of GUCY2C-targeted therapeutics may offer new hope for patients with colorectal cancer worldwide.
- The Ad5-GUCY2C vaccine and advanced CAR-T cell therapies are key components of this GUCY2C-targeted approach.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...